Impact of platelet inhibition level on subsequent no-reflow in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction
- PMID: 28583820
- DOI: 10.1016/j.acvd.2016.12.017
Impact of platelet inhibition level on subsequent no-reflow in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction
Abstract
Background: High P2Y12 platelet reactivity (PR) level after primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI) affects prognosis and may induce the no-reflow phenomenon.
Aim: To investigate the role of PR in the genesis of microvascular obstruction.
Methods: Patients with STEMI undergoing PPCI within 12hours of symptoms onset were included prospectively. All patients received a 600mg clopidogrel-loading dose before PPCI and 250mg aspirin. PR was measured thereafter during PPCI while wiring the culprit lesion and before coronary dilatation, using the P2Y12 VerifyNow® assay. No-reflow was defined as ST-segment regression<50% observed 90minutes after PPCI.
Results: Between January 2014 and November 2015, 140 STEMI patients were included, and divided into two groups: a low PR group (LPR) defined as PR<209P2Y12 reaction units (PRU); and a high PR group (HPR) defined as PR≥209PRU. There were no differences in baseline characteristics between LPR and HPR groups, including age (57.8±11.9 vs. 59.4±13.2 years, respectively; P=0.44) and weight (76.1±15.1 vs. 74.8±10.9kg, respectively; P=0.55). Delay to revascularization was 270.1±175.5 vs. 295.6±206.2minutes (P=0.49) and time between clopidogrel-loading and PR measurement was 53±37 vs 65±54minutes (P=0.29) in the LPR and HPR groups, respectively. No-reflow was more frequent in the HPR group (44 [47.3%] vs. 9 [19.1%]; P=0.0012). Mean PR was higher in patients with no-reflow: 268.3±53 vs. 223.8±50.1 PRU (P=0.002). In multivariable analysis, HPR was an independent predictor of no-reflow. Area under the receiver operating characteristic curve was 0.745 (0.654, 0.835); the cut-off value predicting no-reflow was 254PRU.
Conclusion: High PR level measured at PPCI is independently associated with no-reflow.
Keywords: Angioplastie primaire; No reflow; No-reflow; Platelet reactivity; Primary PCI; Réactivité plaquettaire; Résolution du segment ST; ST-segment resolution.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.
Similar articles
-
Observational Study of Platelet Reactivity in Patients Presenting With ST-Segment Elevation Myocardial Infarction Due to Coronary Stent Thrombosis Undergoing Primary Percutaneous Coronary Intervention: Results From the European PREvention of Stent Thrombosis by an Interdisciplinary Global European Effort Registry.JACC Cardiovasc Interv. 2017 Dec 26;10(24):2548-2556. doi: 10.1016/j.jcin.2017.09.019. JACC Cardiovasc Interv. 2017. PMID: 29268884
-
Novel role of platelet reactivity in adverse left ventricular remodelling after ST-segment elevation myocardial infarction: The REMODELING Trial.Thromb Haemost. 2017 May 3;117(5):911-922. doi: 10.1160/TH16-10-0744. Epub 2017 Feb 2. Thromb Haemost. 2017. PMID: 28150852
-
A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study.JACC Cardiovasc Interv. 2012 Mar;5(3):281-9. doi: 10.1016/j.jcin.2012.01.009. JACC Cardiovasc Interv. 2012. PMID: 22440493
-
Invasive Assessment of the Coronary Microcirculation in Reperfused ST-Segment-Elevation Myocardial Infarction Patients: Where Do We Stand?Circ Cardiovasc Interv. 2017 Mar;10(3):e004373. doi: 10.1161/CIRCINTERVENTIONS.116.004373. Circ Cardiovasc Interv. 2017. PMID: 28242607 Review.
-
Crushed/chewed administration of potent P2Y12 inhibitors in ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: Systematic review and meta-analysis.Platelets. 2022 Jul 4;33(5):679-686. doi: 10.1080/09537104.2021.1974370. Epub 2021 Sep 2. Platelets. 2022. PMID: 34472997
Cited by
-
Prehospital crushed versus integral prasugrel loading dose in STEMI patients with a large myocardial area.EuroIntervention. 2024 Apr 1;20(7):e436-e444. doi: 10.4244/EIJ-D-23-00618. EuroIntervention. 2024. PMID: 38562070 Free PMC article.
-
The Role of Microvascular Obstruction and Intra-Myocardial Hemorrhage in Reperfusion Cardiac Injury. Analysis of Clinical Data.Rev Cardiovasc Med. 2024 Mar 14;25(3):105. doi: 10.31083/j.rcm2503105. eCollection 2024 Mar. Rev Cardiovasc Med. 2024. PMID: 39076959 Free PMC article. Review.
-
Increase in the risk of clopidogrel resistance and consequent TIMI flow impairment by DNA hypomethylation of CYP2C19 gene in STEMI patients undergoing primary percutaneous coronary intervention (PPCI).Pharmacol Res Perspect. 2021 Apr;9(2):e00738. doi: 10.1002/prp2.738. Pharmacol Res Perspect. 2021. PMID: 33641235 Free PMC article.
-
A historical literature review of coronary microvascular obstruction and intra-myocardial hemorrhage as functional/structural phenomena.J Biomed Res. 2023 Jul 28;37(4):281-302. doi: 10.7555/JBR.37.20230021. J Biomed Res. 2023. PMID: 37503711 Free PMC article.
-
Relationship of serum vitamin D levels with coronary thrombus grade, TIMI flow, and myocardial blush grade in patients with acute ST-segment elevation myocardial infarction.Egypt Heart J. 2020 Nov 23;72(1):84. doi: 10.1186/s43044-020-00118-5. Egypt Heart J. 2020. PMID: 33226540 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous